Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a Healthcare company (Biotechnology) with a market capitalization of $187M. The Maz Rating grades it against the other companies in its sector.
Cartesian Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.12, Cartesian Therapeutics, Inc. trades at 180.9x sales. Over the last twelve months it generated about $1M of revenue and a net loss of $151M. It runs an operating margin of -10009.2% and a net margin of -12635.1%. It shows return on equity of 97.7%, return on invested capital of -33.8% and a free cash flow yield of -47.9%. On the balance sheet: a debt-to-equity ratio of -0.46 and a current ratio of 8.38. Over the past 52 weeks the share price ranged from $5.60 to $11.00, with a beta of 0.62.
Cartesian Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cartesian Therapeutics, Inc. (RNAC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 24.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 54.2% / 30% · Interest income / Revenue 120200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 24.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 54.2% / 33% · Receivables / Mkt Cap (36m) 0.02% / 49% · Interest income / Revenue 120200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 24.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 54.2% / 33.33% · Receivables / Mkt Cap (24m) 0.02% / 33.33% · Interest income / Revenue 120200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 9.65% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 42.9% / 33.33% · Receivables / Avg Assets (4Q) 0.14% / 33.33% · Interest income / Revenue 120200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 18.5% / 33.33% · (Cash+ST Inv) / Total Assets 41.8% / 33.33% · (Cash+Recv) / Total Assets 41.8% / 33.33% · Interest income / Revenue 120200000.0% / 5% | Fail |
No. As of September 2026, Cartesian Therapeutics, Inc. (RNAC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cartesian Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 120200000.0% of each dividend: Cartesian Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.